A detailed history of Virtus ETF Advisers LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 10,266 shares of COGT stock, worth $84,078. This represents 0.05% of its overall portfolio holdings.

Number of Shares
10,266
Previous 10,081 1.84%
Holding current value
$84,078
Previous $84,000 30.95%
% of portfolio
0.05%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.24 - $11.48 $1,524 - $2,123
185 Added 1.84%
10,266 $110,000
Q2 2024

Aug 14, 2024

SELL
$6.01 - $9.04 $44,389 - $66,769
-7,386 Reduced 42.29%
10,081 $84,000
Q1 2024

May 15, 2024

SELL
$4.38 - $9.02 $5,251 - $10,814
-1,199 Reduced 6.42%
17,467 $117,000
Q4 2023

Feb 15, 2024

BUY
$4.06 - $10.08 $44,521 - $110,537
10,966 Added 142.42%
18,666 $109,000
Q3 2023

Nov 07, 2023

SELL
$9.69 - $13.34 $7,383 - $10,165
-762 Reduced 9.0%
7,700 $75,000
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.24 $935 - $1,257
95 Added 1.14%
8,462 $100,000
Q1 2023

May 15, 2023

SELL
$10.04 - $15.5 $32,218 - $49,739
-3,209 Reduced 27.72%
8,367 $90,000
Q4 2022

Feb 14, 2023

BUY
$10.65 - $14.84 $123,284 - $171,787
11,576 New
11,576 $133,000
Q2 2022

Aug 12, 2022

SELL
$3.92 - $9.73 $76,251 - $189,267
-19,452 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$5.31 - $8.7 $6,148 - $10,074
-1,158 Reduced 5.62%
19,452 $146,000
Q4 2021

Feb 14, 2022

SELL
$7.51 - $10.81 $20,464 - $29,457
-2,725 Reduced 11.68%
20,610 $177,000
Q3 2021

Nov 15, 2021

SELL
$5.99 - $9.14 $7,301 - $11,141
-1,219 Reduced 4.96%
23,335 $196,000
Q2 2021

Aug 10, 2021

SELL
$7.82 - $9.3 $27,737 - $32,987
-3,547 Reduced 12.62%
24,554 $199,000
Q1 2021

May 17, 2021

BUY
$7.47 - $12.34 $209,914 - $346,766
28,101 New
28,101 $247,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $539M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.